Precision Cancer Screenings
Helpful news
We’ve put together some news & updates to help you learn more about us and what we do. Have questions? Contact us today!
Jul, 2026
Behavioral Diagnostics and Versiti Clinical Trial Solutions Announce Partnership to Bring Objective Smoking and Alcohol Exposure Screening to Clinical Trials
Partnership gives trial sponsors access to epigenetic assays designed to support participant screening, risk stratification and data integrity.
Aug, 2016
Behavioral Diagnostics Awarded Grant to Commercialize a Precision Medicine Test for Guiding Smoking Therapy
August 2016: Behavioral Diagnostics (BD) LLC is pleased to announce that the National Institutes of Health has awarded it the first installment of a $900,000 project to develop a quantitative test for smoking that uses saliva DNA.
May, 2016
Behavioral Diagnostics Awarded Grant to Commercialize Epigenetic Alcohol Test
May 2016: Behavioral Diagnostics Inc. (BDI) is pleased to announce that the National Institutes of Health has awarded it a $1.4 million grant to complete the initial commercialization of an epigenetic test for the detection of heavy alcohol consumption.